Our content provides subscribers with unique insight and breaking news regarding the most complex mergers and regulatory situations around the world.
InquireOur work combines cutting edge breaking news with in-depth analysis to better inform readers how policy and regulation affects market competition.
Learn MoreOur editorial team reconstructs the policy process to yield market insight for a community of subscribers including government regulators, lawyers, investors, and non-profits.
Learn MoreInvestigative news & analysis on how policy affects market competition
REQUEST A TRIALIn leaning toward suing to block Tapestry’s (TPR) proposed buyout of Capri...
Apr 15, 2024
The FTC is leaning toward a lawsuit to block Tapestry’s (TPR) proposed $8.5...
Apr 12, 2024
Focus on DOJ in NAR broker fee litigation. All eyes in the real estate industry...
Apr 12, 2024
On the latest episode of The Capitol Forum’s Second Request podcast,...
Apr 03, 2024
Hear senior policy analyst at Economic Liberties Shahid Naeem discuss his...
Mar 28, 2024
Investigative news & analysis on how policy affects market competition
REQUEST A TRIALWe are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy issues.
"The Capitol Forum’s articles include a good mix of investigative journalism combined with expert analysis and opinion."
"Capitol Forum’s comprehensive and diligent reporting on key competitive issues provides helpful insights on and contributes to the vigorous debate around antitrust policy and enforcement."
"I rely on Capitol Forum daily for its valuable combination of timely information and unique insights on key deals and cases. It offers viewpoints and analyses that others don’t, which has become particularly valuable in the current policy environment."
"Capitol Forum is a critical resource because it strikes a unique balance of reporting on breaking stories in antitrust, providing in-depth analysis, and offering a behind the scenes glimpse into the politics and personalities driving modern antitrust enforcement."
"I rely on Capitol Forum to get insight and analysis that’s often unavailable from other sources. Their coverage of FTC and DOJ matters is top-notch."
“The Capitol Forum is the only team covering this incredibly important beat. Better yet, their work is deeply intelligent, influential, and almost always right.”
“I appreciate the helpful work done by The Capitol Forum. It’s one of the sources I turn to for information about what activity is out there not only in the antitrust space, but also in the consumer protection world.”
“The Capitol Forum provides an always interesting and sometimes surprising look under the hood about pending antitrust activities.”
“I have become an avid reader of The Capitol Forum because it provides timely in-depth news and analysis of the myriad legal, business, legislative and political factors affecting business developments. I always come away with fresh perspectives that help me advise my clients about current issues.”
“The Capitol Forum has been an indispensable resource for me in analyzing regulatory risk affecting companies in my portfolio or watch list.”
“The Capitol Forum consistently provides timely and sophisticated news and analysis of important M & A transactions. It’s the real deal!”
"Unlike most media outlets, The Capitol Forum digs deep into incredibly complex issues of great importance, providing timely and relevant analysis that you can use to inform your work."
Analysis of select corporate transcripts through the lens of Joseph Harrington’s landmark paper, “Collusion in Plain Sight: Firms’ use of Public Announcements to Restrain Competition.”
Get an inside view of the biologics market, where rebate schemes appear to drive market share. You’ll learn how a complex system supports sluggish biosimilar uptake and other types of anticompetitive conduct.
The Capitol Forum has recently published a special report with an extract of reporting that has been done analyzing price, market share and generic formulary exclusion data to spot anticompetitive conduct.